Garden Biotech: Subsidiary Obtains Drug Registration Certificate

Garden Biotech Announcement, its wholly-owned subsidiary Zhejiang Garden Pharmaceutical Co., Ltd. recently received the "Ezetimibe Atorvastatin Calcium Tablets (I)" drug registration certificate approved and issued by the National Medical Products Administration. This medication is mainly used to treat hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). According to Minet Data, the market size for Ezetimibe Atorvastatin Calcium Tablets (I) in public medical institutions is approximately 56.6 million yuan in 2025. Obtaining this drug registration certificate will further enrich the company's product line, promote product development upgrades, and have a positive impact on the company's growth.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned